Inosine
Research reviewed: Up until 03/2026
Inosine is a dietary supplement with 8 published peer-reviewed studies involving 250 participants, researched for Neuroprotection & Multiple Sclerosis, Uric Acid & Antioxidant Support.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Neuroprotection & Multiple Sclerosis
ModerateUric Acid & Antioxidant Support
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Neuroprotection & Multiple Sclerosis
To assess inosine + interferon beta vs interferon beta alone in RRMS (ASIIMS trial)
Study Type
Randomised controlled trial
Purpose
To assess inosine + interferon beta vs interferon beta alone in RRMS (ASIIMS trial)
Dose
Dose titrated to achieve uric acid 6-7 mg/dL
Participants
86 RRMS patients on interferon beta
Duration
2 years
Results
Inosine + interferon beta trended toward disability reduction vs interferon beta alone. Uric acid significantly elevated in inosine group without serious adverse effects. PMID: 20200198
How They Measured It
Disability accumulation, relapse rate, uric acid levels
To evaluate inosine + interferon association in MS relapse and disability
Study Type
Randomised controlled trial
Purpose
To evaluate inosine + interferon association in MS relapse and disability
Dose
Inosine to achieve uric acid 6 mg/dL
Participants
48 MS patients
Duration
2 years
Results
Inosine combination showed trends toward fewer relapses and reduced disability progression. Uric acid elevation safely achieved. PMID: 25313094
How They Measured It
EDSS, relapse rate, MRI outcomes
To assess oral inosine for peroxynitrite inactivation in MS patients
Study Type
Pilot clinical study
Purpose
To assess oral inosine for peroxynitrite inactivation in MS patients
Dose
Oral inosine to elevate uric acid
Participants
11 MS patients
Duration
Variable
Results
Inosine elevated uric acid levels, inactivating peroxynitrite. Three of 11 patients showed clinical improvement; no disease progression observed. PMID: 11724447
How They Measured It
Uric acid levels, clinical assessment, peroxynitrite markers
To assess therapeutic value of inosine-induced uric acid elevation in MS
Study Type
Clinical study
Purpose
To assess therapeutic value of inosine-induced uric acid elevation in MS
Dose
Oral inosine escalating dose
Participants
30 MS patients
Duration
12 months
Results
Inosine safely elevated serum uric acid levels in MS patients. Inverse correlation between uric acid levels and MS disease activity confirmed. PMID: 17121380
How They Measured It
Uric acid elevation, MS disability outcomes
Uric Acid & Antioxidant Support
To investigate inosine neuroprotection in Parkinson's disease model via uric acid
Study Type
Animal study
Purpose
To investigate inosine neuroprotection in Parkinson's disease model via uric acid
Dose
500 mg/kg oral inosine
Participants
Mice with MPTP-induced Parkinsonism
Duration
2 weeks
Results
Inosine administration elevated uric acid and significantly protected dopaminergic neurons against MPTP toxicity, supporting neuroprotective role of uric acid. PMID: 18842097
How They Measured It
Dopaminergic neuron loss, motor function, uric acid levels
To assess inosine on axonal growth and recovery after spinal cord injury
Study Type
Animal study
Purpose
To assess inosine on axonal growth and recovery after spinal cord injury
Dose
Sustained inosine administration
Participants
Rats with spinal cord injury
Duration
12 weeks
Results
Inosine significantly promoted axonal growth and improved motor recovery after partial spinal cord injury by activating purinergic signalling pathways. PMID: 11880503
How They Measured It
Axonal sprouting, motor recovery
To assess inosine safety and uric acid elevation in Parkinson's disease (SURE-PD)
Study Type
Randomised controlled trial
Purpose
To assess inosine safety and uric acid elevation in Parkinson's disease (SURE-PD)
Dose
500-3000 mg/day oral inosine
Participants
75 Parkinson's disease patients
Duration
25 weeks
Results
Inosine safely elevated uric acid by 2.3 mg/dL in PD patients without serious adverse events. Supports feasibility of disease modification trials. PMID: 24974748
How They Measured It
Safety, uric acid levels, motor and non-motor PD measures
To review inosine as a neuroprotective agent and uric acid precursor across neurological conditions
Study Type
Review
Purpose
To review inosine as a neuroprotective agent and uric acid precursor across neurological conditions
Dose
Various
Participants
N/A
Duration
N/A
Results
Inosine elevates uric acid, a potent antioxidant and peroxynitrite scavenger. Evidence supports neuroprotective role in MS, Parkinson's, and spinal cord injury through multiple mechanisms.
How They Measured It
Comprehensive literature review
Frequently Asked Questions
Common questions about Inosine research
There are currently 8 peer-reviewed studies on Inosine (Inosine), involving 250 total participants. Research covers Neuroprotection, Multiple sclerosis, Uric acid elevation. The overall evidence strength is rated as Moderate.
The evidence is currently rated as "Moderate Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (5 human studies, 2 animal studies), and reported outcomes.
Inosine has been researched for: Neuroprotection, Multiple sclerosis, Uric acid elevation. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 5 out of 8 studies are human trials. The remaining 2 are animal studies. Human trials carry more weight in our evidence scoring system.
